Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor.
References:
[1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 35, No. 4, 2021.
[2]. Masugi Y, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017 Aug;66(8):1463-1473.
















